Last updated: 2026-10-19 16:49:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Sagimet Biosciences Inc. (SGMT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.61, with a market capitalization of $568.69M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.50 to $11.45. This page covers its latest market performance, valuation, price trends and company information.
$568.69M | |
$8.24 | |
$20.71 | |
$1.73 | |
$8.02 | |
531.14K | |
1.27M | |
-- | |
$11.45 | |
$4.50 | |
-- | |
-- |
Sagimet Biosciences Inc. (SGMT) is currently trading at $8.61 as of 2026-10-19 16:33:00, up 7.38% ($0.59) from the previous close of $8.02
During today's regular trading session, SGMT has traded between $1.73 and $20.71, with a trading volume of 531.14K shares. The current price is near the middle of today's range.
Over the past seven days, Sagimet Biosciences Inc. (SGMT) moved from $8.92 to $8.61, representing a decline of 3.45% ($0.31).
The stock traded between $7.51 and $9.15 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 1.42 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 59.2%
SGMT is currently trading at $8.61, placing it 59.2% of the way from its 52-week low of $4.50 to its 52-week high of $11.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sagimet Biosciences Inc. (SGMT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.